The midlife metabolic transition is rarely a straight line. For many women navigating perimenopause and menopause, sudden changes in body composition and energy can feel like an overnight shift – one that doesn’t seem to care about unchanged workout routines or strict diets. While the public conversation around health innovations like GLP-1 medications remains heavily focused on surface-level weight loss, the underlying endocrinology tells a far more profound story about systemic resilience.
To map out this complex territory, we spoke with Dr. Angela D. Mazza, a triple board-certified endocrinologist specializing in thyroid health, metabolic disorders, and regenerative medicine, who also lends her expertise to Kilo’s Medical Advisory Board. In this conversation, she breaks down the hidden biology of the menopausal transition, the role of metabolic therapies, and how continuous health data is reshaping tailored care for women.
The Estrogen Trap
For a woman going through perimenopause, why is it a mistake to only focus on the number on the scale?
Midlife weight gain is often just the visible sign of a much deeper metabolic shift. During perimenopause, a woman’s body experiences complex changes in insulin sensitivity, body composition, systemic inflammation, sleep architecture, stress physiology, and appetite signaling. While GLP-1 medications are now popular for supporting weight loss, the larger goal is to build long-term metabolic resilience. We aim for better blood glucose control, a reduction in harmful visceral fat, improved daily energy levels, preservation of lean muscle, and an overall healthier cardiometabolic trajectory for the future.
Many women notice that even if they don’t change their diet or workouts, they suddenly start gaining belly fat and losing energy. What causes this?
Estrogen is a powerful hormone that naturally supports women’s insulin sensitivity, mitochondrial function, and a healthy pattern of fat distribution around the hips and thighs. As estrogen declines during midlife, the body naturally becomes more insulin resistant, even if a woman’s diet and exercise habits stay the same. This shift promotes greater fat storage around the abdomen while cellular energy production becomes less efficient, contributing to fatigue and other metabolic changes.
Since symptoms like fatigue and cravings are usually blamed entirely on fluctuating hormones, how does improving insulin sensitivity actually quiet down these disruptive midlife changes?
Sex hormones matter immensely, but blood glucose stability matters just as much. When glucose and insulin levels are fluctuating wildly throughout the day, women experience severe energy crashes, intense sugar cravings, irritability, poor sleep, and increased hunger. Stabilizing blood glucose reduces these dramatic swings and prevents the body from feeling metabolically “chaotic.” By improving insulin sensitivity and appetite regulation, GLP-1s help quiet these systemic disruptions, making a woman’s energy, hunger, and body composition feel far more manageable and predictable during the menopausal transition.
Coding for Long-Term Healthspan
Given that menopausal women are already at a heightened risk for bone and muscle loss, how do you structure a GLP-1 treatment plan to ensure rapid weight loss targets fat tissue rather than critical lean mass and physical strength?
I never want GLP-1 treatment to simply be “weight loss at any cost.” For midlife women, the therapeutic plan must explicitly protect muscle, bone density, and long-term physical function.
In practice, that requires ensuring adequate protein intake, consistent resistance training, close attention to vitamin D, calcium, magnesium, and other vital micronutrients, alongside careful monitoring to prevent overly rapid weight loss. Clinically, I also assess a patient’s thyroid status, sex hormones, inflammatory markers, and lifestyle factors like sleep and stress. The ultimate objective is high-quality fat loss with total preservation of lean mass, physical strength, and metabolic rate.
With rapid advancements in next-generation metabolic medicine, how do you see emerging therapies shifting our overall approach to healthy aging and longevity for women?
The next generation of incretin-based therapies will move us completely away from weight loss alone and toward highly personalized metabolic medicine. Upcoming triple agonists and combination approaches will allow clinicians to target appetite, insulin resistance, liver metabolism, systemic inflammation, and energy balance with unprecedented precision. For women in midlife and beyond, these advancements could become a foundational element of a broader healthy-aging strategy. The focus will shift permanently toward comprehensive cardiometabolic risk reduction, muscle preservation, cognitive health, and mobility, rather than just lowering a BMI score.
As a member of Kilo’s Medical Advisory Board, how do you envision health and wellness solutions using continuous, real-life data and supplements to help midlife women successfully navigate the complex hormonal and metabolic changes?
There is a major opportunity right now to combine deep medical insight with continuous, real-world tracking. Midlife women are not static biological entities; their sleep quality, cravings, stress levels, glucose patterns, weight, energy, and digestion can change dramatically from week to week. Digital health tools excel at identifying these subtle, fluctuating patterns that are easily missed during a traditional, infrequent office visit.
When we pair these real-life data streams with evidence-informed supplementation, personalized nutrition, tailored exercise guidance, and medical oversight, we give women the power to individualize their approach. It makes them feel genuinely supported through perimenopause and menopause. That is exactly why Kilo’s work is so exciting – it bridges advanced digital technology, clinical science, and real-life human experience to preserve healthspan when it matters most.